Savara (SVRA) is in focus after reporting second quarter and first half 2026 results that showed a higher net loss than a year earlier, along with a new shelf registration for up to $108.297 million in common stock.

The latest earnings update and shelf registration arrived after a strong 1 year total shareholder return of 76.97%, even though the year to date share price return is down 4.61% and shorter term momentum has cooled.

If Savara has you looking at risk and reward around clinical milestones, this is a good time to widen your watchlist and scan 42 healthcare AI stocks

After a 1 year run that still looks strong on paper, and a recent pullback alongside wider losses and a fresh shelf in place, does Savara’s current price still offer enough potential upside to justify the added dilution and clinical risk?

Preferred Price-to-Book Multiple of 9.5x: Is It Justified?

At a last close of $5.38, Savara trades on a P/B of 9.5x, which places the stock at a much richer level than both the US Biotechs industry and its peer group.

The price to book ratio compares the company’s market value to its net asset value. For a clinical stage biopharma stock like Savara, investors often lean on this metric when earnings are still negative and revenue is limited, because it gives a sense of how much is being paid for each dollar of equity on the balance sheet.

Here, the valuation is clearly punchy. Savara’s 9.5x P/B is well above the US Biotechs industry average of 2.4x and also above the 3.5x peer average. That wide gap suggests the market is assigning a premium that goes beyond what similar companies trade on, and any shift in sentiment around clinical progress or funding needs could matter more when starting from this level.

Investors weighing this kind of premium against balance sheet strength and clinical timelines may want a deeper breakdown of how the current ratio stacks up, which is covered in the valuation analysis See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 9.5x (OVERVALUED)

However, you also need to weigh the risk of further equity dilution from the new shelf and consider the possibility that clinical or regulatory timelines for Savara slip.

Next Steps

With sentiment on Savara split between concern over risks and interest in potential rewards, this is a moment to move quickly and test your own view using the 1 key reward and 2 important warning signs.

Looking for more investment ideas beyond Savara?

If Savara has sharpened your focus on risk and reward, do not stop here. Use these focused stock ideas to pressure test and strengthen your broader portfolio view.

• Target resilience by reviewing companies highlighted in the 80 resilient stocks with low risk scores to see which stocks carry lower overall risk scores.
• Hunt for value by scanning the screener containing 20 high quality undiscovered gems and spot lesser known stocks with strong fundamentals that the market may be overlooking.
• Build staying power by checking the solid balance sheet and fundamentals stocks screener (51 results) so you can focus on companies backed by healthier financial foundations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.